½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1414127

¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå º¸°í¼­(2024³â)

Conjugate Vaccine Global Market Report 2024

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Business Research Company | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Á¢ÇÕ¹é½Å½ÃÀå ±Ô¸ð´Â ÃÖ±Ù ¸î ³âµ¿¾È ºü¸£°Ô ¼ºÀåÇÏ¿© 2023³â 167¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2024³â¿¡´Â 191¾ï 1,000¸¸ ´Þ·¯¿¡ À̸£°í, ¿¬Æò±Õ 13.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áö³­ ±â°£ µ¿¾È ³ªÅ¸³­ È®´ë´Â Áúº´ ºÎ´ã, Á¤ºÎ ÁÖµµÀÇ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥, ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼Ò¾Æ ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ °ü½É, ¿¹¹æ ÀÇ·áÀÇ ÀϹÝÀûÀÎ Ãß¼¼ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

Á¢ÇÕ¹é½Å ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³âµ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2028³â±îÁö ¿¬Æò±Õ 12.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 306¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀº ¿¹¹æÁ¢Á¾ Á¤Ã¥ÀÇ È®´ë, °í·ÉÈ­ »çȸÀÇ º¯È­, »õ·Î¿î ¹é½Å ÀûÀÀÁõÀÇ ÃâÇö, ¼¼°è º¸°Ç ¾Èº¸¿¡ ´ëÇÑ °ü½É Áõ°¡, ±¹Á¦ Çù·Â ³ë·Â, °æÁ¦ ¹ßÀüÀÇ ¿µÇâ µî ´Ù¾çÇÑ ¿äÀο¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¸ñÇÒ ¸¸ÇÑ µ¿ÇâÀ¸·Î´Â È¿À²ÀûÀÎ ¹é½Å º¸±ÞÀ» À§ÇÑ Çù·Â ¹× ÆÄÆ®³Ê½Ê °­È­, °íÀ§Ç豺 ´ë»ó ¸ÂÃãÇü Á¢±Ù¹ý, ½ÅÁ¾ °¨¿°º´¿¡ ´ëÇÑ ¹é½Å Àû¿ë, ¹é½Å Á¦Á¶ ±â¼úÀÇ ¹ßÀü, ¹é½Å ÇüÆò¼º ½ÇÇö¿¡ ÃÊÁ¡À» µÐ ¼¼°è º¸°Ç ¼¼°è º¸°Ç¿¡ ´ëÇÑ ³ë·Â µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.

°áÇÕÇü ¹é½Å ½ÃÀåÀÇ ¼ºÀå Àü¸ÁÀÇ ¹è°æ¿¡´Â ¼ºÀÎÀÇ ¹é½Å »ç¿ë Áõ°¡°¡ ÀÖ½À´Ï´Ù. °áÇÕÇü ¹é½ÅÀº ¼¼±Õ¼º ĸ½¶Çü ´Ù´ç·ù¿¡ ´ëÇÑ °­·ÂÇÑ ¸é¿ª ¹ÝÀÀÀ» À¯µµÇÏ¿© ¼¼±Õ °¨¿°¿¡ ´ëÇÑ ½ÅüÀÇ ¹æ¾î·ÂÀ» °­È­Çϱâ À§ÇØ Æ¯º°È÷ °í¾ÈµÈ ¹é½ÅÀÔ´Ï´Ù. ¼ºÀο¡°Ô Àû¿ëÇÏ¸é ¸é¿ª ¹ÝÀÀÀ» °­È­ÇÏ¿© ÁßÁõÈ­, ÇÕº´Áõ ¹× ¼¼±Õ¼º ÁúȯÀÇ ÀüÆÄ À§ÇèÀ» ÁÙÀÌ´Â ¿ªÇÒÀ» Çϸç, National Center for Immunization Research and Surveillance°¡ ¹ßÇ¥ÇÑ 2020³âºÎÅÍ 2022³â±îÁö Historical National Influenza Vaccination Coverage º¸°í¼­¿¡ µû¸£¸é, 2022³â ¸» 15¼¼ ÀÌ»ó 50¼¼ ¹Ì¸¸ÀÇ ¹é½Å Á¢Á¾·üÀº 29.5%·Î 2021³â 22.8%¿¡¼­ Å« ÆøÀ¸·Î Áõ°¡Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀÎ Á¢ÇÕ¹é½Å »ç¿ëÀÇ ±ÞÁõÀº Á¢ÇÕ¹é½Å ½ÃÀå ¼ºÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù.

°áÇÕ¹é½Å ½ÃÀåÀÇ ¼ºÀå Àü¸ÁÀº °¨¿°¼º ÁúȯÀÇ ¹ß»ý·ü Áõ°¡·Î µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º, ±â»ýÃæ, °õÆÎÀÌ µî º´¿ø¼º ¹Ì»ý¹°¿¡ ÀÇÇÑ °¨¿°Àº °øÁߺ¸°Ç¿¡ Å« À§ÇùÀÌ µÇ°í ÀÖ½À´Ï´Ù. 2022³â 10¿ù ¹ü¹Ìº¸°Ç±â±¸ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2021³â¿¡´Â ¾à 1,060¸¸ ¸íÀÌ °áÇÙ¿¡ °¨¿°µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2020³â¿¡´Â 4,000¸¸ ¸íÀÌ °áÇÙ¿¡ °¨¿°µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2020³â ´ëºñ 4.5% Áõ°¡ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ Áß 160¸¸ ¸íÀÌ °áÇÙÀ¸·Î »ç¸ÁÇß°í, HIV °¨¿°ÀÚ Áß 18¸¸7000¸íÀÌ »ç¸ÁÇß½À´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â °áÇÕÇü ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù.

ºÏ¹Ì´Â 2023³â ¼¼°è Á¢ÇÕ¹é½Å ½ÃÀå¿¡¼­ °¡Àå ±Ô¸ð°¡ Å« Áö¿ªÀ̾ú½À´Ï´Ù. Á¢ÇÕ¹é½Å ½ÃÀå º¸°í¼­ÀÇ ´ë»ó Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ¼­À¯·´, µ¿À¯·´, ºÏ¹Ì, ³²¹Ì, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Ư¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

  • °íÀÎÇ÷¹À̼ÇÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • ¿ìÅ©¶óÀ̳ª¡¤·¯½Ã¾Æ ÀüÀïÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¼ºÀå

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±Ô¸ð¿Í ¼ºÀå ½ÇÀû, 2018-2023³â
  • ½ÃÀå ±Ô¸ð¿Í ¼ºÀå ¿¹Ãø, 2023-2028³â, 2033³â

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, Á¦Ç° À¯Çüº° ¼¼ºÐÈ­, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â
  • ´Ü°¡
  • ´Ù°¡
  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, º´¿øüº° ¼¼ºÐÈ­, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â
  • ¼¼±Õ
  • ¹ÙÀÌ·¯½º
  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, Áúȯ ÀûÀÀº° ¼¼ºÐÈ­, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â
  • Æó·Å±¸±Õ
  • ÀÎÇ÷翣ÀÚ
  • ¼ö¸·¿°±Õ
  • ÀåƼǪ½º
  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, ȯÀÚº° ¼¼ºÐÈ­, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â
  • ¼Ò¾Æ
  • ¼ºÀÎ
  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº° ¼¼ºÐÈ­, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â
  • º´¿ø
  • Ŭ¸®´Ð
  • ȨÄɾî
  • ±âŸ

Á¦7Àå Áö¿ª ¹× ±¹°¡º° ºÐ¼®

  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, Áö¿ªº°, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â
  • ¼¼°èÀÇ Á¢ÇÕ¹é½Å ½ÃÀå, ±¹°¡º°, ºÐ¼® ¹× ¿¹Ãø, 2018-2023³â, 2023-2028³â, 2033³â

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

  • Á¢ÇÕ¹é½Å ½ÃÀå °æÀï ±¸µµ
  • Á¢ÇÕ¹é½Å ½ÃÀå ±â¾÷ °³¿ä
    • Sanofi SA
    • Pfizer Inc.
    • Merck &Co. Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech International Limited

Á¦31Àå °æÀï º¥Ä¡¸¶Å·

Á¦32Àå °æÀï ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÇâÈÄ Àü¸Á°ú °¡´É¼º ºÐ¼®

Á¦35Àå ºÎ·Ï

LSH 24.02.05

“Conjugate Vaccine Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugate vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugate vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The conjugate vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product Type: Monovalent Conjugate Vaccines; Multivalent Conjugate Vaccine
  • 2) By Pathogen: Bacterial; Viral
  • 3) By Disease Indication: Pneumococcal; Influenza; Meningococcal; Typhoid
  • 4) By Patient: Pediatric; Adults
  • 5) By End-User: Hospitals; Clinics; Homecare Settings; Other End Users
  • Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; GlaxoSmithKline plc; Bharat Biotech International Limited
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Conjugate vaccines, also referred to as immunogen conjugates, represent advanced immune system modulators extensively employed to induce protection against invading pathogens or stimulate specific antibodies against a targeted molecule. The conjugation process plays a crucial role in augmenting the immune response, enabling a more effective recognition of the pathogen by the immune system.

Two primary types of conjugate vaccines are monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent conjugate vaccines consist of a single conjugated antigen, typically designed to target a specific pathogen or strain. These vaccines are utilized for preventing infections caused by bacteria with a polysaccharide capsule, such as streptococcus pneumoniae, haemophilus influenzae type B, and neisseria meningitidis. Monovalent conjugate vaccines are developed to address various diseases, including pneumococcal, influenza, meningococcal, and typhoid. They find application in pediatric and adult patient populations and are utilized in diverse healthcare settings such as hospitals, clinics, homecare, and other medical facilities.

The conjugate vaccine research report is one of a series of new reports from The Business Research Company that provides conjugate vaccine market statistics, including the conjugate vaccine industry's global market size, regional shares, competitors with a conjugate vaccine market share, detailed conjugate vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the conjugate vaccine industry. This conjugate vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugate vaccine market size has grown rapidly in recent years. It will grow from $16.77 billion in 2023 to $19.11 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The expansion observed in the historical period can be attributed to several factors, including the burden of diseases, government-driven immunization programs, heightened awareness regarding vaccination, a focus on pediatric vaccination, and the prevailing trends in preventive healthcare.

The conjugate vaccine market size is expected to see rapid growth in the next few years. It will grow to $30.65 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecasted period can be attributed to a range of factors, including the expansion of immunization policies, the dynamics of an aging population, the emergence of new vaccine indications, heightened global health security concerns, international collaboration efforts, and the impact of economic development. Noteworthy trends expected in this period include increased collaborations and partnerships for efficient vaccine distribution, tailored approaches targeting high-risk populations, the application of vaccines in emerging infectious diseases, advancements in vaccine manufacturing technologies, and global health initiatives focused on achieving vaccine equity.

The anticipated growth in the conjugate vaccine market is driven by the increasing utilization of these vaccines among adults. Conjugate vaccines are specifically formulated to elicit a robust immune response against bacterial capsular polysaccharides, fortifying the body's defenses against bacterial infections. Their application in the adult population serves to mitigate the risk of severe illness, complications, and the transmission of bacterial diseases by bolstering the immune response. As evidenced by the Historical National Influenza Vaccination Coverage report spanning 2020-2022 from the National Centre for Immunization Research and Surveillance, vaccination coverage for the 15 - < 50 years age group reached 29.5% at the end of 2022, showcasing a notable increase from the 22.8% recorded in 2021. This upsurge in the use of conjugate vaccines for adults is a significant driver of the growth in the conjugate vaccine market.

The projected expansion of the conjugate vaccine market is underpinned by the rising incidence of infectious diseases. Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, pose significant public health challenges. Conjugate vaccines play a pivotal role in preventing infectious diseases, particularly those caused by specific bacteria, and are especially crucial for vulnerable populations such as infants and young children. According to the Pan American Health Organization's data from October 2022, approximately 10.6 million individuals contracted tuberculosis (TB) in 2021, marking a 4.5% increase from 2020. Among those affected, 1.6 million individuals succumbed to TB, including 187,000 cases among people living with HIV. This escalating incidence of infectious diseases is a key factor propelling the growth of the conjugate vaccine market.

Innovation in conjugate vaccines emerges as a prominent trend gaining traction in the conjugate vaccine market. Companies actively involved in this market are strategically focused on the development of innovative conjugate vaccines to maintain their competitive standing. An exemplar of this trend is Pfizer Inc., a US-based pharmaceutical and biotechnology company, which, in June 2022, launched Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine is designed to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 includes conjugates for the 13 serotypes covered by PREVNAR 13, along with conjugates for seven additional serotypes associated with invasive pneumococcal disease, characterized by high case-fatality rates, antibiotic resistance, and meningitis.

Major companies operating in the conjugate vaccine market are directing their efforts towards the development of advanced conjugate vaccines, including the 21-valent pneumococcal conjugate vaccine. This type of vaccine is crafted to provide protection against infections caused by Streptococcus pneumoniae bacteria. An illustrative example is Merck & Co., Inc., a US-based pharmaceutical company, which, in April 2022, received the Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its 'V116.' V116 is a 21-valent pneumococcal conjugate vaccine designed for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. Tailored to target strains of pneumococcal bacteria commonly found in adults, V116 represents a significant advancement in conjugate vaccine development.

In August 2022, GSK, a UK-based pharmaceutical and biotechnology company, completed the acquisition of Affinivax Inc. for $2.1 billion. This strategic move by GSK is aimed at fortifying its portfolio of specialty medicines and vaccines, particularly in the realm of advanced pneumococcal vaccines. The acquisition includes Affinivax's AFX3772, contributing to GSK's position in the development of cutting-edge conjugate vaccines. Affinivax, a US-based biotechnology company, specializes in the development of conjugate vaccines.

Major companies operating in the conjugate vaccine market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., AstraZeneca plc, Johnson & Johnson, Moderna Inc., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Inovio Pharmaceuticals Inc., Medicago Inc., Mitsubishi Tanabe Pharma Corporation, Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

North America was the largest region in the global conjugate vaccine market in 2023. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the conjugate vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The conjugate vaccine market consists of sales of diphtheria, tetanus, and pertussis (DTaP) conjugate vaccine, haemophilus influenza type b (Hib) conjugate vaccine, and E. coli conjugate vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Conjugate Vaccine Market Characteristics

3. Conjugate Vaccine Market Trends And Strategies

4. Conjugate Vaccine Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Conjugate Vaccine Market Size and Growth

  • 5.1. Global Conjugate Vaccine Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Conjugate Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Conjugate Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Conjugate Vaccine Market Segmentation

  • 6.1. Global Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monovalent Conjugate Vaccines
  • Multivalent Conjugate Vaccine
  • 6.2. Global Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bacterial
  • Viral
  • 6.3. Global Conjugate Vaccine Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
  • 6.4. Global Conjugate Vaccine Market, Segmentation By Patient, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatric
  • Adults
  • 6.5. Global Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Homecare Settings
  • Other End Users

7. Conjugate Vaccine Market Regional And Country Analysis

  • 7.1. Global Conjugate Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Conjugate Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Conjugate Vaccine Market

  • 8.1. Asia-Pacific Conjugate Vaccine Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Conjugate Vaccine Market

  • 9.1. China Conjugate Vaccine Market Overview
  • 9.2. China Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Conjugate Vaccine Market

  • 10.1. India Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Conjugate Vaccine Market

  • 11.1. Japan Conjugate Vaccine Market Overview
  • 11.2. Japan Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Conjugate Vaccine Market

  • 12.1. Australia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Conjugate Vaccine Market

  • 13.1. Indonesia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Conjugate Vaccine Market

  • 14.1. South Korea Conjugate Vaccine Market Overview
  • 14.2. South Korea Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Conjugate Vaccine Market

  • 15.1. Western Europe Conjugate Vaccine Market Overview
  • 15.2. Western Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Conjugate Vaccine Market

  • 16.1. UK Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Conjugate Vaccine Market

  • 17.1. Germany Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Conjugate Vaccine Market

  • 18.1. France Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Conjugate Vaccine Market

  • 19.1. Italy Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Conjugate Vaccine Market

  • 20.1. Spain Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Conjugate Vaccine Market

  • 21.1. Eastern Europe Conjugate Vaccine Market Overview
  • 21.2. Eastern Europe Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Conjugate Vaccine Market

  • 22.1. Russia Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Conjugate Vaccine Market

  • 23.1. North America Conjugate Vaccine Market Overview
  • 23.2. North America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Conjugate Vaccine Market

  • 24.1. USA Conjugate Vaccine Market Overview
  • 24.2. USA Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Conjugate Vaccine Market

  • 25.1. Canada Conjugate Vaccine Market Overview
  • 25.2. Canada Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Conjugate Vaccine Market

  • 26.1. South America Conjugate Vaccine Market Overview
  • 26.2. South America Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Conjugate Vaccine Market

  • 27.1. Brazil Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Conjugate Vaccine Market

  • 28.1. Middle East Conjugate Vaccine Market Overview
  • 28.2. Middle East Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Conjugate Vaccine Market

  • 29.1. Africa Conjugate Vaccine Market Overview
  • 29.2. Africa Conjugate Vaccine Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Conjugate Vaccine Market, Segmentation By Pathogen, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Conjugate Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Conjugate Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Conjugate Vaccine Market Competitive Landscape
  • 30.2. Conjugate Vaccine Market Company Profiles
    • 30.2.1. Sanofi S.A.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. GlaxoSmithKline plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bharat Biotech International Limited
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Conjugate Vaccine Market Competitive Benchmarking

32. Global Conjugate Vaccine Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Conjugate Vaccine Market

34. Conjugate Vaccine Market Future Outlook and Potential Analysis

  • 34.1 Conjugate Vaccine Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Conjugate Vaccine Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Conjugate Vaccine Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦